预约演示
更新于：2025-05-16
Cloxacillin Sodium
氯唑西林钠
更新于：2025-05-16
概要
基本信息
在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 加拿大 (1963-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H20ClN3NaO6S |
InChIKeyKNNWTOJBVOKDPC-VICXVTCVSA-N |
CAS号7081-44-9 |
关联
9
项与 氯唑西林钠 相关的临床试验IRCT20220310054247N1
Investigating the effect of a topical gel containing Sumac extract and Cloxacillin on diabetic foot ulcer: a double-blind placebo-controlled trial
NCT04141787
Ceftriaxone as Home Intravenous Therapy for Deep-Seated Staphylococcal Infections, a Randomized Non-Inferiority Trial
IRCT20120215009014N272
Effect of using Cloxacillin as an Antibiotic Lock Solution versus placebo on prevention of catheter-associated infection in hemodialysis patients: a single-blind randomized clinical trial
100 项与 氯唑西林钠 相关的临床结果
登录后查看更多信息
100 项与 氯唑西林钠 相关的转化医学
登录后查看更多信息
100 项与 氯唑西林钠 相关的专利（医药）
登录后查看更多信息
5,213
项与 氯唑西林钠 相关的文献（医药）2025-05-06ACS Omega
Membrane-Active Peptides Derived from Natural Transmembrane Domains Function as Antibiotic Potentiators
Article
作者: Johnson, Tyler S. ; Deber, Charles M.
Antimicrobial resistance continues to be a prevailing threat to human health worldwide, largely due to the arsenal of resistance mechanisms bacteria have evolved over years of exposure to traditional antibiotics. As an approach to devising therapeutics that can overcome this resistance, we hypothesized that peptides consisting of single transmembrane (TM) segments of membrane proteins may permeabilize bacterial membranes and thereby facilitate access of antimicrobials to their cytoplasmic targets. Using peptides derived from a natural TM helix from the AcrB component of the AcrAB-TolC efflux protein, we found that AcrB TM8 (wild type sequence: KKKK-FL(Abu)LAALYESWSI-NH2) and a "scrambled" analog of identical composition, charge, and overall hydrophobicity (TM8-S: KKKK-FSLEALW(Abu)ISAYL-NH2) (Abu = α-aminobutyric acid), resensitize Escherichia coli to sublethal doses of the antibiotics cloxacillin and nalidixic acid. These peptides induce 50-100% reduction of cell growth compared to bacteria treated with either peptide or antibiotic alone. The molecular basis for peptide-based permeabilization of the bacterial outer and inner membranes that contributes to the observed antibiotic potentiation was studied through several in vitro liposome-based assays and in vivo fluorescence-based assays. The overall results suggest that membrane proteins harbor a wealth of peptide sequences that may function as effective membrane-active peptides for the targeting of difficult-to-treat Gram-negative bacterial infections, and as such, provide valuable guidelines for the design of membrane-active peptides with synergistic antibacterial and antibiotic potentiation activity.
2025-05-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Performance of two combination disk methods as confirmation for ESBL and AmpC presence in clinical Enterobacterales isolates
Article
作者: Bode, L G M ; Klaassen, C H W ; Zandijk, W H A ; Doornekamp, L ; Goessens, W H F
PURPOSE:
Guidelines recommend the use of a combination disk method (CDM) including cefepime and clavulanic acid as a confirmation method for ESBL detection. However, an alternative CDM containing cloxacillin (combining ceftazidime and cefotaxime with clavulanic acid and/or cloxacillin), is not only able to confirm ESBL presence, but also to provide information about AmpC production. We aim to show non-inferiority of the cloxacillin-CDM compared to the cefepime-CDM.
METHODS:
We collected 102 individual clinical Enterobacterales isolates that were positive in the ESBL screening with the VITEK II. Phenotypic confirmation was performed with a cefepime-CDM and a cloxacillin-CDM (Rosco®). These results were compared with the results of a multiplex ESBL real-time PCR and an in-house developed conventional AmpC PCR.
RESULTS:
Twenty-eight% of the isolates were positive in the ESBL PCR (CTX-M, SHV-2, TEM-3). The results of cefepime-CDM and cloxacillin-CDM were concordant with the ESBL PCR in respectively 99 and 94 %. The cefepime-CDM had a sensitivity of 100 % (95 % confidence interval (CI) 88,1-100) and specificity of 98,6 % (95 % CI 92,6-100). The cloxacillin-CDM had a sensitivity of 96,6 (95 % CI 82,2-99,9) and a specificity of 93,2 % (95 % CI 84,7-97,7). The cloxacillin-CDM in the group I Enterobacterales compared to the AmpC PCR had a sensitivity of 92 % (95 % CI 62-100) and a specificity of 100 % (95 % CI 77-100).
CONCLUSION:
Both cefepime-CDM and cloxacillin-CDM performed well as ESBL confirmation methods. Therefore, we suggest to add the cloxacillin-CDM as an alternative ESBL confirmation method to AMR detection guidelines in clinical settings.
2025-05-01CLINICAL MICROBIOLOGY AND INFECTION
Cefazolin versus Antistaphylococcal Penicillins for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Systematic Review and Meta-Analysis
Review
作者: Jager, Nynke G L ; Ghanem-Zoubi, Nesrin ; Lee, Todd C ; Daneman, Nick ; Tong, Steven Y C ; Goodman, Anna L ; Kouijzer, Ilse ; Ong, Sean W X ; Kaasch, Achim J ; McDonald, Emily G ; Davis, Joshua S ; Noutsios, Dean ; Prosty, Connor ; McMullan, Brendan J
BACKGROUND:
There is debate on whether cefazolin or antistaphylococcal penicillins should be the first-line treatment for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Ongoing trials are investigating whether cefazolin is non-inferior to (flu)cloxacillin, but it remains uncertain whether these findings apply to other antistaphylococcal penicillins.
OBJECTIVE:
We conducted a systematic review and meta-analysis comparing cefazolin to each of the individual antistaphylococcal penicillins for MSSA bacteremia.
METHODS:
Data SourcesWe updated a 2019 systematic review but specifically focused on evaluating outcomes by individual antistaphylococcal penicillins.Study Eligibility CriteriaComparative observational studies.ParticipantsPatients with MSSA bacteremia.InterventionsCefazolin versus the antistaphylococcal penicillins.Assessment of Risk of BiasThe risk of bias in non-randomized studies of interventions tool.Methods of Data SynthesisThe primary outcome was 30-day all-cause mortality and we assessed for non-inferiority of cefazolin using a prespecified non-inferiority margin of a pooled odds ratio (OR) <1.2 using raw unadjusted data. Secondary outcomes were 90-day mortality, treatment-related adverse events (TRAEs), discontinuation due to toxicity, and nephrotoxicity.
RESULTS:
No randomized data have been published. 30 observational studies at moderate or high risk of bias were included, which comprised 3869 patients who received cefazolin and 11644 patients who received antistaphylococcal penicillins (flucloxacillin=6721, unspecified=2440, nafcillin=1305, cloxacillin=1258, and oxacillin=120). Cefazolin was associated with a reduced odds of 30-day all-cause mortality (OR=0.73, 95%CI=0.62-0.85) compared to antistaphylococcal penicillins, meeting pre-specified non-inferiority. This effect was consistent versus flucloxacillin (OR=0.92, 95%CI=0.73-1.16), nafcillin (OR=0.58, 95%CI=0.28-1.17), cloxacillin (OR=0.42, 95%CI=0.11-1.58), and oxacillin (OR=0.31, 95%CI=0.03-2.75). Point estimates favored cefazolin for 90-day mortality, TRAEs, nephrotoxicity, and discontinuation due to toxicity overall and in each comparison with individual antistaphylococcal penicillins, except for TRAEs versus cloxacillin.
CONCLUSIONS:
In moderate to low quality observational data, cefazolin was non-inferior for mortality and potentially superior for safety as compared to antistaphylococcal penicillins overall and across most individual comparisons.
100 项与 氯唑西林钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 葡萄球菌感染 | 加拿大 | 1963-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用